Valuation: Prostatype Genomics AB

Market Cap 8.61M 889K 780K 723K 665K 1.26M 85.13M 1.28M 3.38M 41.81M 3.34M 3.27M 144M P/E 2024
-0.38x
P/E 2025 -0.23x
Enterprise Value 4.84M 500K 439K 406K 374K 707K 47.89M 721K 1.9M 23.52M 1.88M 1.84M 81.21M EV / Sales 2024
33.9x
EV / Sales 2025 23.6x
Free-Float
27.07%
Yield 2024 *
-
Yield 2025 -
1 day+62.20%
1 week-36.56%
Current month-45.12%
1 month-58.60%
3 months-70.57%
6 months-69.11%
Current year-21.33%
1 week 0.14
Extreme 0.1405
0.39
1 month 0.14
Extreme 0.1405
0.94
Current year 0.14
Extreme 0.1405
2.28
1 year 0.14
Extreme 0.1405
2.28
3 years 0.14
Extreme 0.1405
438
5 years 0.14
Extreme 0.1405
17,940
10 years 0.14
Extreme 0.1405
18,400
Manager TitleAgeSince
Chief Executive Officer - 2016-12-31
Director of Finance/CFO - 2023-10-30
General Counsel - 2023-02-28
Director TitleAgeSince
Chairman - 2016-12-31
Director/Board Member - 2017-12-31
Director/Board Member 74 2018-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+62.20%-36.56%-74.35%-99.94% 893K
-0.20%-5.00%+70.44%+430.82% 38.66B
+0.58%-2.03%+11.54%+31.59% 22.7B
-1.46%-1.51%-23.11%-39.58% 7.3B
-2.26%-6.51%+13.85%+110.62% 5.16B
+1.91%+4.82%+17.90%+44.90% 2.97B
-2.99%-7.39%-22.56%+817.99% 1.95B
-1.17%0.00%+33.47%-19.89% 1.84B
+0.14%-6.66%+97.08%-18.58% 1.84B
+5.26%+3.51%+25.97%+4.38% 1.75B
Average +6.15%-6.16%+15.02%+126.23% 8.42B
Weighted average by Cap. -0.20%-2.62%+37.82%+229.55%

Financials

2024 2025
Net sales 1.92M 198K 174K 161K 148K 280K 18.96M 286K 752K 9.31M 744K 728K 32.16M 594K 61.35K 53.81K 49.84K 45.86K 86.74K 5.87M 88.42K 233K 2.88M 230K 225K 9.96M
Net income -41.05M -4.24M -3.72M -3.44M -3.17M -5.99M -406M -6.11M -16.1M -199M -15.92M -15.57M -688M -44.5M -4.6M -4.03M -3.73M -3.44M -6.5M -440M -6.62M -17.45M -216M -17.26M -16.88M -746M
Net Debt -9.35M -966K -847K -785K -722K -1.37M -92.46M -1.39M -3.67M -45.4M -3.63M -3.55M -157M -3.77M -389K -341K -316K -291K -550K -37.25M -561K -1.48M -18.29M -1.46M -1.43M -63.17M
Logo Prostatype Genomics AB
Prostatype Genomics AB is a Sweden-based company developing gene tests. The Company's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.
Employees
7
Date Price Change Volume
26-07-13 SEK 0.2360 +62.20% 6,884,167
26-07-10 SEK 0.1455 -27.25% 1,227,854
26-07-09 SEK 0.2000 -11.11% 1,108,989
26-07-08 SEK 0.2250 +1.81% 951,489
26-07-07 SEK 0.2210 -40.59% 2,613,691
  1. Stock Market
  2. Stocks
  3. PROGEN Stock